Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR3 | Q99500 | 14/20 | 0.58 |
| ▸ | S1PR1 | P21453 | 10/20 | 0.58 |
| ▸ | S1PR2 | O95136 | 9/20 | 0.58 |
| ▸ | LPAR2 | Q9HBW0 | 5/20 | 0.58 |
| ▸ | S1PR4 | O95977 | 4/20 | 0.48 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | CNR1 | P21554 | 1/20 | 0.38 |
| ▸ | CNR2 | P34972 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15633485 | 0.89 | S1PR3 (0.58) | S1PR3S1PR1S1PR2LPAR2S1PR4 | |
| SCHEMBL15633496 | 0.85 | S1PR3 (0.54) | S1PR3S1PR1S1PR2LPAR2S1PR4 | |
| SCHEMBL15633592 | 0.85 | S1PR3 (0.78) | S1PR3S1PR1S1PR2LPAR2S1PR4 | |
| SCHEMBL15634454 | 0.84 | S1PR3 (0.55) | S1PR3S1PR1S1PR2LPAR2S1PR4 | |
| SCHEMBL15633313 | 0.84 | S1PR3 (0.80) | S1PR3S1PR1S1PR2LPAR2S1PR4 | |
| SCHEMBL15706891 | 0.83 | SMN1; SMN2 (0.39) | S1PR3S1PR1S1PR2LPAR2SMN1; SMN2 | |
| SCHEMBL15671604 | 0.83 | L3MBTL1 (0.39) | S1PR3S1PR1S1PR2LPAR2SMN1; SMN2 | |
| SCHEMBL15633314 | 0.83 | S1PR3 (0.75) | S1PR3S1PR1S1PR2LPAR2S1PR4 | |
| SCHEMBL16011021 | 0.79 | S1PR1 (0.63) | S1PR3S1PR1S1PR2LPAR2S1PR4 | |
| SCHEMBL15633629 | 0.79 | L3MBTL1 (0.48) | S1PR3S1PR1SMN1; SMN2TSHRMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140274963-A1 | SUBSTITUTED ARYL 1 ,2,4-OXADIAZOLES DERIVATIVES AS SPHINGOSINE-1 PHOSPHATE RECEPTORS MODULATORS | ALLERGAN, INC. (US) | 2014-09-18 | — | — | US | claimed |
| US-8722712-B2 | Substituted aryl 1 ,2,4-oxadiazoles derivatives as sphingosine-1 phosphate receptors modulators | ALLERGAN, INC. (US) | 2014-05-13 | — | — | US | claimed |
| US-20140100199-A1 | SUBSTITUTED ARYL 1 ,2,4-OXADIAZOLES DERIVATIVES AS SPHINGOSINE-1 PHOSPHATE RECEPTORS MODULATORS | ALLERGAN, INC. (US) | 2014-04-10 | — | — | US | claimed |
| WO-2014055916-A1 | SUBSTITUTED ARYL-1,2,4-OXADIAZOLE DERIVATIVES USEFUL FOR THE TREATMENT OF INTERALIA OCULAR OR INFLAMMATORY DISEASES | ALLERGAN, INC. (US) | 2014-04-10 | — | — | WO | claimed |
| US-20140274963-A1 | SUBSTITUTED ARYL 1 ,2,4-OXADIAZOLES DERIVATIVES AS SPHINGOSINE-1 PHOSPHATE RECEPTORS MODULATORS | ALLERGAN, INC. (US) | 2014-09-18 | — | — | US | disclosed |
| US-20140274963-A1 | SUBSTITUTED ARYL 1 ,2,4-OXADIAZOLES DERIVATIVES AS SPHINGOSINE-1 PHOSPHATE RECEPTORS MODULATORS | ALLERGAN, INC. (US) | 2014-09-18 | — | — | US | disclosed |
| US-8722712-B2 | Substituted aryl 1 ,2,4-oxadiazoles derivatives as sphingosine-1 phosphate receptors modulators | ALLERGAN, INC. (US) | 2014-05-13 | — | — | US | disclosed |
| US-8722712-B2 | Substituted aryl 1 ,2,4-oxadiazoles derivatives as sphingosine-1 phosphate receptors modulators | ALLERGAN, INC. (US) | 2014-05-13 | — | — | US | disclosed |
| US-20140100199-A1 | SUBSTITUTED ARYL 1 ,2,4-OXADIAZOLES DERIVATIVES AS SPHINGOSINE-1 PHOSPHATE RECEPTORS MODULATORS | ALLERGAN, INC. (US) | 2014-04-10 | — | — | US | disclosed |
| WO-2014055916-A1 | SUBSTITUTED ARYL-1,2,4-OXADIAZOLE DERIVATIVES USEFUL FOR THE TREATMENT OF INTERALIA OCULAR OR INFLAMMATORY DISEASES | ALLERGAN, INC. (US) | 2014-04-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140274963-A1 | SUBSTITUTED ARYL 1 ,2,4-OXADIAZOLES DERIVATIVES AS SPHINGOSINE-1 PHOSPHATE RECEPTORS MODULATORS | S1PR3, S1PR1, S1PR4 | S1PR3 1/4885S1PR1 2/4885S1PR2 4/4885 |
| US-20140100199-A1 | SUBSTITUTED ARYL 1 ,2,4-OXADIAZOLES DERIVATIVES AS SPHINGOSINE-1 PHOSPHATE RECEPTORS MODULATORS | S1PR3, S1PR1, S1PR4 | S1PR3 1/4885S1PR1 2/4885S1PR2 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.